Estrogen receptor-alpha, breast cancer patients and tamoxifen response
Key points
- Approximately 50% of breast carcinomas are resistant to tamoxifen.
- The association between recurrence-free survival and ER-alpha S118-P expression in tumor tissue was investigated.
- 72.2 recurrences per 1000 person-years) but not among patients whose tumors had low expression (51.0 vs.
- "Our study highlights the importance of assessing the functionality of a drug target," the authors write.
Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute.
Approximately 50% of breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that ER-alpha S118-P is required for response to tamoxifen.
Göran Landberg, M.D., Ph.D., of the Breakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology at the University of Manchester, and colleagues evaluated data from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs. no systemic treatment. The association between recurrence-free survival and ER-alpha S118-P expression in tumor tissue was investigated.
Researchers found evidence of a statistically significant recurrence-free survival benefit from adjuvant tamoxifen, compared with no systemic treatment, among patients whose tumors had high ER-alpha S118-P expression (23.7 vs. 72.2 recurrences per 1000 person-years) but not among patients whose tumors had low expression (51.0 vs. 57.0 recurrences per 1000 person-years). ER-alpha S118-P was not associated with a benefit among untreated patients.
"Our study highlights the importance of assessing the functionality of a drug target," the authors write. "Future studies are necessary to evaluate whether ER-alpha S118-P expression is associated with tamoxifen response among post-menopausal patients."
###
Contact: Göran Landberg, [email protected], +4640331953 (Sweden)
Note to Reporters: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.
Visit JNCI online at http://jnci.oxfordjournals.org and the JNCI press room at http://www.oxfordjournals.org/our_journals/jnci/press_room.html
For the latest cancer news and studies, follow us on Twitter @JNCI_Now
Contact: Steve Graff
[email protected]
301-841-1285
Journal of the National Cancer Institute
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsScientists Break Genetic Code for Estrogen-Positive Breast Cancer
A group of Canadian researchers have decoded the genetic structure of metastatic lobular breast cancer. This major breakthough could lead to further advancement in the fight against the disease by assisting scientists…
15 October 2009
NewsSoy reduces breast cancer risk by receptor status
Rather than protecting against all breast cancers, high levels of soy food consumption appears to specifically reduce the risk of estrogen receptor (ER)-positive tumors and human epidermal growth factor receptor 2…
17 October 2008
NewsAnti-estrogen Drug Therapy Reduces Risk of Invasive Breast Cancer in Older Women
New analysis of a drug approved for osteoporosis prevention and treatment has provided definitive evidence that the medication is also effective as a breast cancer preventative for certain cancers. Women who took the…
